zidebactam dihydrate and cefepime hydrochloride

FDA Drug Profile — ZAYNICH

zidebactam dihydrate and cefepime hydrochloride is listed in the FDA National Drug Code directory with 1 NDC code, marketed under brand name including ZAYNICH. Available dosage form: injection, powder, for solution.

Drug Details

Generic Name
zidebactam dihydrate and cefepime hydrochloride
Brand Names
ZAYNICH
Application Number
NDA220787
Sponsor
Wockhardt Suisse USA LLC
NDC Codes
1
Dosage Forms
INJECTION, POWDER, FOR SOLUTION
Routes
INTRAVENOUS
Active Ingredients
ZIDEBACTAM DIHYDRATE, CEFEPIME HYDROCHLORIDE

Indications and Usage

1 INDICATIONS AND USAGE ZAYNICH is a combination of cefepime, a cephalosporin antibacterial, and zidebactam, a beta-lactamase inhibitor and non-beta-lactam antibacterial indicated for the treatment of adult patients with complicated urinary tract infections (cUTI) including pyelonephritis caused by designated susceptible microorganisms. ( 1.1 ) Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZAYNICH and other antibacterial drugs, ZAYNICH should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) 1.1 Complicated Urinary Tract Infections, including Pyelonephritis ZAYNICH is indicated for the treatment of adult patients with complicated urinary tract infections (cUTI) including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter cloacae complex, and Pseudomonas aeruginosa . 1.2 Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZAYNICH and other antibacterial drugs, ZAYNICH should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.